Showing results (151-160 of 205) with videos related to
Sort By:
Pageof 21
Annals of Surgical Oncology|January 7, 2022
Cytoreductive Surgery and Intraperitoneal Chemotherapy in Advanced Serous Epithelial Ovarian Cancer: A 14-Year French Retrospective Single-Center Study of 124 PatientsBrice Paquette, Elsa Kalbacher, Frédéric Mercier, et al.Advanced Healthcare Materials|March 6, 2024
Supramolecular Heterodimer Peptides Assembly for Nanoparticles FunctionalizationClélia Mathieu, Shayamita Ghosh, Julien Draussin, et al.Journal of Cachexia, Sarcopenia and Muscle|April 4, 2022
Chemotherapy impairs skeletal muscle mitochondrial homeostasis in early breast cancer patientsJoris Mallard, Elyse Hucteau, Anne-Laure Charles, et al.Bulletin Du Cancer|August 6, 2014
[Economic assessment of the routine use of Oncotype DX® assay for early breast cancer in Franche-Comte region]Virginie Nerich, Elsa Curtit, Fernando Bazan, et al.Small (Weinheim an Der Bergstrasse, Germany)|January 1, 2023
Clinically Translatable Transcrocetin Delivery Platform for Correction of Tumor Hypoxia and Enhancement of Radiation Therapy EffectsMarie-Charlotte Diringer, Pierre Coliat, Clélia Mathieu, et al.BMC Cancer|March 11, 2014
Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II studyThomas Bachelot, Jose A Garcia-Saenz, Sunil Verma, et al.Frontiers in Cardiovascular Medicine|October 10, 2022
Cardiotoxicity is mitigated after a supervised exercise program in HER2-positive breast cancer undergoing adjuvant trastuzumabQuentin Jacquinot, Nathalie Meneveau, Antoine Falcoz, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancerLuca Gianni, Gilles H Romieu, Michail Lichinitser, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2018
Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive Early Breast CancerXavier Pivot, Igor Bondarenko, Zbigniew Nowecki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2009
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancerStephen Johnston, John Pippen, Xavier Pivot, et al.Pageof 21